Generation Bio Company Leadership
| GBIO Stock | USD 0.41 0.11 21.15% |
Generation Bio employs about 115 people. The company is managed by 15 executives with a total tenure of roughly 269 years, averaging almost 17.0 years of service per executive, having 7.67 employees per reported executive. Analysis of Generation Bio's management performance can provide insight into the firm performance.
Generation | Build AI portfolio with Generation Stock |
Generation Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.1897) % which means that it has lost $0.1897 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7006) %, meaning that it created substantial loss on money invested by shareholders. Generation Bio's management efficiency ratios could be used to measure how well Generation Bio manages its routine affairs as well as how well it operates its assets and liabilities.Generation Bio Workforce Comparison
Generation Bio Co is rated # 5 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,340. Generation Bio holds roughly 115 in number of employees claiming about 9% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.93) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.77) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.77. Generation Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Generation Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Generation Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Generation Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nicholson Donald William 3 days ago Acquisition by Nicholson Donald William of 30000 shares of Generation Bio at 0.3874 subject to Rule 16b-3 | ||
Mcdonough Geoff few days ago Disposition of 5273 shares by Mcdonough Geoff of Generation Bio subject to Rule 16b-3 | ||
Stehman-breen Catherine over a month ago Acquisition by Stehman-breen Catherine of 30000 shares of Generation Bio at 0.3874 subject to Rule 16b-3 | ||
Appelhans Dannielle over a month ago Acquisition by Appelhans Dannielle of 30000 shares of Generation Bio at 0.3874 subject to Rule 16b-3 | ||
Kevin Conway over three months ago Disposition of 587 shares by Kevin Conway of Generation Bio subject to Rule 16b-3 | ||
Kevin Conway over three months ago Insider Trading | ||
Paone Antoinette over three months ago Disposition of 1592 shares by Paone Antoinette of Generation Bio subject to Rule 16b-3 | ||
Phillip Samayoa over three months ago Acquisition by Phillip Samayoa of 1147 shares of Generation Bio subject to Rule 16b-3 |
Generation Bio Notable Stakeholders
A Generation Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Generation Bio often face trade-offs trying to please all of them. Generation Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Generation Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Caitlin MBA | Senior Development | Profile | |
| Robert Kotin | CoFounder Advisor | Profile | |
| Sara Besten | Chief Officer | Profile | |
| Tracy Zimmermann | Chief Officer | Profile | |
| Phillip Samayoa | Chief Officer | Profile | |
| Jasmin Tower | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile | |
| Cameron MD | CEO and President | Profile | |
| MD MBA | Chief Officer | Profile | |
| Esq JD | Chief Officer | Profile | |
| Yalonda JD | Chief Secretary | Profile | |
| Mark Angelino | CoFounder | Profile | |
| Kevin Conway | Chief Officer | Profile | |
| Matthew Stanton | Chief Officer | Profile | |
| MS MBA | Chief Officer | Profile |
About Generation Bio Management Performance
The success or failure of an entity such as Generation Bio often depends on how effective the management is. Generation Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Generation management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Generation management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Generation Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 150 people.
Generation Bio Workforce Analysis
Traditionally, organizations such as Generation Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Generation Bio within its industry.Generation Bio Manpower Efficiency
Return on Generation Bio Manpower
| Revenue Per Employee | 173K | |
| Revenue Per Executive | 1.3M | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 8.8M | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 10.5M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Generation Bio Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Generation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.